Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a
| Year | Firm | Period | Expenses | Doc |
|---|---|---|---|---|
| 2017 | THE CONAFAY GROUP, LLC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Termination |
— | |
| 2017 | THE CONAFAY GROUP, LLC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | |
| 2016 | THE CONAFAY GROUP, LLC |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | |
| 2016 | THE CONAFAY GROUP, LLC |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | |
| 2016 | THE CONAFAY GROUP, LLC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | |
| 2016 | THE CONAFAY GROUP, LLC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | |
| 2015 | THE CONAFAY GROUP, LLC |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | |
| 2015 | THE CONAFAY GROUP, LLC |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | |
| 2015 | THE CONAFAY GROUP, LLC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | |
| 2015 | THE CONAFAY GROUP, LLC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— |
| Firm | Filings | Expenses |
|---|---|---|
| THE CONAFAY GROUP, LLC | 11 | — |
| Issue | Activities |
|---|---|
| Health Issues | 11 |
| Medicare/Medicaid | 11 |